Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NXP900 · 3 trials · 12 indications
Best response of complete response (CR) or partial response (PR) per RECIST 1.1
Confirmed CR or PR from the first documented response to the date of documented disease progression or death.
The proportion of patients with stable disease (SD), partial response (PR), or complete response (CR).
Best response of complete response (CR) or partial response (PR) per RECIST 1.1 (or mRECIST 1.1 for subjects with pleural mesothelioma).
Confirmed CR or PR from the first documented response to the date of documented disease progression or death.
The proportion of patients with stable disease (SD), partial response (PR), or complete response (CR).
| Arm | Type | Description |
|---|---|---|
| Dose Exploration | EXPERIMENTAL | Escalating doses of NXP900 given with lorlatinib |
| Dose Exploration (Part 1) | EXPERIMENTAL | Escalating doses of NXP900 given with osimertinib |
| Dose Escalation (Part A) | EXPERIMENTAL | Escalating doses of NXP900 are planned with a starting dose level of 20 mg once per day. |
| Dose Expansion (Part B) | EXPERIMENTAL | Participants will receive the selected dose of NXP900 |
| Name | Type | Description |
|---|---|---|
| NXP900 | DRUG | NXP900 is an orally administered inhibitor of SRC family kinases (SFK) |
| Lorlatinib | DRUG | Lorlatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) |
| Osimertinib | DRUG | Osimertinib is an orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor |
Inclusion Criteria: * 18 years old or older * Unresectable, metastatic or locally advanced ALK-positive NSCLC. * Must have received lorlatinib as first or second line TKI * One prior line of systemic chemotherapy is permitted * Must have tolerated the dose level of lorlatinib actively being explore...
NXP900 is an investigational small molecule being studied in oncology for ALK positive cancers, advanced solid tumors, and EGFR mutation positive non-small cell lung cancer. It is not yet approved for any indication and remains in Phase 1 clinical development under Nuvectis Pharma.
NXP900 targets SRC and YES1, two kinases involved in cancer cell signaling. By inhibiting SRC/YES1, the drug is designed to interfere with pathways that support tumor growth and resistance. This targeted approach is being tested in solid tumors and specific lung cancer subtypes.
NXP900 is being developed by Nuvectis Pharma, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker NVCT. The company is responsible for advancing the drug through clinical trials.
NXP900 is in Phase 1 clinical development. It is investigational and has not received FDA approval. The Phase 1 program includes multiple recruiting and active studies evaluating the drug in advanced solid tumors and non-small cell lung cancer.
NXP900 is being evaluated in three Phase 1 trials: NCT07784959 testing NXP900 with lorlatinib in ALK+ lung cancer, NCT07315113 testing NXP900 with osimertinib in EGFR-mutated NSCLC, and NCT05873686 studying NXP900 in advanced cancers including NSCLC and renal cancer.